Drug Profile


Alternative Names: APL2

Latest Information Update: 11 May 2017

Price : $50

At a glance

  • Originator Apellis Pharmaceuticals
  • Class Antianaemics; Cyclic peptides; Eye disorder therapies
  • Mechanism of Action Complement C3 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Paroxysmal nocturnal haemoglobinuria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Wet age-related macular degeneration
  • Phase I Ischaemia; Paroxysmal nocturnal haemoglobinuria

Most Recent Events

  • 06 Jun 2017 Apellis Pharmaceuticals plans the AIRIS phase I trial in Healthy volunteers in New Zealand (ACTRN12617000822381p)
  • 09 May 2017 APL 2 receives Orphan Drug status for Paroxysmal nocturnal haemoglobinuria in European Union
  • 20 Dec 2016 APL 2 receives Fast Track designation for Paroxysmal nocturnal haemoglobinuria [SC,Injection] (Second-line therapy or greater) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top